Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Risk factors for early relapse in patients with biliary tract cancers who underwent curative resection: An exploratory subgroup analysis of JCOG1202.
Authors
Hiroaki Yanagimoto
Kobe University Graduate School of Medicine, Kobe, Japan;
Hiroaki Yanagimoto , Kohei Nakachi , Masafumi Ikeda , Masaru Konishi , Gakuto Ogawa , Yusuke Sano , Tatsuya Nomura , Hiroo Yanagibashi , Kazuto Shibuya , Hirofumi Shirakawa , Amane Takahashi , Yoshihiro Sakamoto , Isamu Makino , Etsuro Hatano , Naoto Gotohda , Masato Ozaka , Takeshi Terashima , Takuji Okusaka , Junji Furuse , Makoto Ueno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000011688
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 541)
DOI
10.1200/JCO.2023.41.4_suppl.541
Abstract #
541
Poster Bd #
C11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.
First Author: Joon Oh Park
Poster
2022 ASCO Annual Meeting
Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396.
First Author: Fatemeh Ardeshir-Larijani
Poster
2021 Gastrointestinal Cancers Symposium
Risk factors for the continuation of S-1 adjuvant chemotherapy for gastric cancer analyzed from the JCOG1104 phase III trial.
First Author: Takanobu Yamada
Poster
2019 ASCO Annual Meeting
Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.
First Author: Miguel J. Gil Gil